Eisai 1Q FY 2008 financial results: Pariet/AcipHex: Ongoing development to enhance value for patients during and beyond DLP.

For its 1Q FY 2008 (period ends 30 Jun 2008), Eisai Co Ltd has reported on developments regarding Pariet/AcipHex. Patent validity and enforceability upheld: US Federal Circuit Court of Appeals fully upheld Eisai's favourable ruling in AcipHex's patent infringement lawsuit against Teva and Dr. Reddys (21 Jul 2008). Extended Release (ER): goal -long-acting 24-hour relief with superior efficacy in erosive GERD. Significantly prolonged pH maintenance period (pH greater than 4) compared with esomeprazole in PK/PD study; Phase III ongoing including head-to-head in erosive GERD. Targeting NDA submission in US in FY2009. AcipHex as a branded product having composition patent, aims to …